MyFinsight
Home
Blog
About
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$7,318K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Non-cash loss (gain) on changes ...
Net increase in cash and cash eq...
Proceeds from issuance of octobe...
Others
Negative Cash Flow Breakdown
Net loss
Net income from discontinued ope...
Dividend paid
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2025-12-31
Net loss
-22,141
Net income from discontinued operations, net of taxes
-11,081
Stock-based compensation expense related to employee and director stock awards
29
Non-cash loss on extinguishment of secured convertible note
0
Non-cash expense incurred to obtain consent of secured convertible note holders
0
Non-cash loss (gain) on changes in fair value of warrant liability
24,486
Non-cash loss on changes in fair value of embedded derivative liability
0
Non-cash loss on modification of warrants
0
Non-cash right-of-use amortization
140
Impairment of long-lived assets
854
Amortization of debt discounts on convertible notes
248
Prepaid expenses and other current assets
445
Other assets
85
Accounts payable and accrued liabilities
-37
Operating lease liabilities
-398
Net cash used in operating activities, continuing operations
-8,430
Net proceeds from issuance of preferred stock-Series DPreferred Stock
3,786
Net proceeds from issuance of preferred stock-Series EPreferred Stock
2,049
Cash payment pursuant to warrant exchange-Series FPreferred Stock
525
Proceeds from warrants exercise-Warrants And Prefunded Warrants
852
Proceeds from issuance of october 2025 pre-funded warrants
5,946
Proceeds from issuance of common stock and pre-funded warrants the 2024 public offering, net of issuance costs-Underwritten Registered Direct Offering
0
Proceeds from bridge loan-Bridge Loan
0
Payment on bridge note
500
Payments on secured convertible notes
0
Payments on warrants purchase
2,001
Payment on redemption of series f preferred stock-Series FPreferred Stock
175
Dividend paid
4,817
Cash debt issuance cost
0
Net cash provided by financing activities, continuing operations
4,615
Net decrease in cash, cash equivalents, and restricted cash, continuing operations
-3,815
Net increase in cash and cash equivalents, discontinued operations
11,133
Net decrease in cash, cash equivalents and restricted cash, consolidated
7,318
Cash, cash equivalents and restricted cash, beginning of year
907
Cash, cash equivalents and restricted cash of continuing operations, end of year
8,225
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in cash
and cash...
$11,133K
Proceeds from issuance of
october 2025 pre-funded...
$5,946K
Net proceeds from
issuance of preferred...
$3,786K
Net proceeds from
issuance of preferred...
$2,049K
Proceeds from warrants
exercise-Warrants And Prefunded...
$852K
Net decrease in
cash, cash...
$7,318K
Canceled cashflow
$3,815K
Net cash provided by
financing activities,...
$4,615K
Canceled cashflow
$8,018K
Net decrease in
cash, cash...
-$3,815K
Canceled cashflow
$4,615K
Non-cash loss (gain) on
changes in fair value of...
$24,486K
Impairment of long-lived
assets
$854K
Amortization of debt
discounts on convertible...
$248K
Non-cash right-of-use
amortization
$140K
Stock-based compensation
expense related to...
$29K
Dividend paid
$4,817K
Payments on warrants
purchase
$2,001K
Cash payment
pursuant to warrant...
$525K
Payment on bridge note
$500K
Payment on redemption of
series f preferred...
$175K
Net cash used in
operating activities,...
-$8,430K
Canceled cashflow
$25,757K
Net loss
-$22,141K
Net income from
discontinued operations, net...
-$11,081K
Prepaid expenses and
other current assets
$445K
Operating lease
liabilities
-$398K
Other assets
$85K
Accounts payable and
accrued liabilities
-$37K
Buy us a coffee